Development of PHY606 as Adjunct Therapy for Anemia Patients

• Status: Completed
• Trial end date: 2019-11-18
• Target enrollment: 0
• Participant gender: All

Summary

Many reasons can cause anemia, decreased RBC production or increased destruction of circulation RBC. The investigators investigate the Danggui Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of genomic and metabolomics in the healthy people and the patiens with anemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sheng-Teng Huang

Criteria

Inclusion Criteria:

• female: Hb<11 g/dL; male: Hb<13.5 g/dL

• has no allergic reaction to TCM

Exclusion Criteria:

• below 20 years old

• ever drug abuse or still in drug abuse

• pregnant or in breast-feeding women

• with psychotic disorders

• cardiac arrhythmia with pacemaker

• dyscoagulation or thrombocytopenia (platelet< 15000/uL) or liver dysfunction (> 2 fold normal range)

• with severe disease (cardiac arrest, heart failure, COPD, GI bleeding, etc.)

• under another clinical trials